Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
Status:
Completed
Trial end date:
2021-07-24
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with
either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice
daily for up to 28 days.